No Patient Left Behind

📢NEW: Check out our new #GCEA calculator. It is an exciting free tool to help identify key value drivers of innovative medicines. Whether you are an investor, innovator, patient advocate, or policy wonk, check it, test it, and please share your feedback! www.nopatientleftbehind.org/gcea-calcula...

Community Sign On Letter - IBX policy excluding coverage for rare disease products approved through Accelerated Approval As organizations representing the rare disease community, we are very concerned about Independence Blue Cross Blue Shield’s (IBX) policy (08.02.35) that excludes coverage for FDA-approved rare disease...

It is awful that Independence BCBS (IBX) health plan thinks its ok to force patients to wait 18 months after @fda.gov accelerated approval to cover a treatment.
📝Please sign the Little Hercules Foundation letter urging IBX to reverse policy
docs.google.com/forms/d/e/1F...
@govmurphy.bsky.social

The Impact of the Inflation Reduction Act on Investment in Innovative Medicines: A Project-Level Analysis - Therapeutic Innovation & Regulatory Science The impact of Medicare’s price negotiation on long-term pharmaceutical innovation and patient welfare remains one of the most widely debated topics across stakeholder groups. Existing policy simulatio...

#IRA’s small molecule penalty disproportionately harms early-stage drug development and has far greater harmful impact on innovation & patients than previously recognized. #CBO should incorporate real-world insights from specialist investors into its models.
link.springer.com/article/10.1...

Price Controls Hinder Treatment Access in Medicare Part D — No Patient Left Behind A new survey demonstrates that a majority of consumers want health plans to lower out-of- pocket costs, but are concerned state government price controls will harm access and not reduce costs

Patients want policies that lower their out-of-pocket costs without restricting access to the treatments they are prescribed—let’s listen to them.

Read the full findings here:

(4/4)

Patients also fear broader impacts because of new policies:

85% worry that plans will withdraw from the market, limiting options.

(3/4)

Of all respondents:

🚫 30% said their insurance denied them a doctor-prescribed drug in the past year, and 17% got no treatment at all.

💊 81% worry that the IRA will force them to switch from their prescribed medications.

💰 92% expect their out-of-pocket costs to increase.

(2/4)

We released new research with Charles River Associates that highlights a growing concern among #Medicare beneficiaries—many want lower out-of-pocket prescription costs but fear that new policies under the IRA will make it harder to get the medicines they need.

🧵

(1/4)

Our Quest to Beat Autoimmune Disorders — No Patient Left Behind Biomedical innovators are developing new autoimmune therapeutics - insurance reform will ensure new treatments and cures are accessible and affordable.

Autoimmune diseases afflict 45 million Americans—and it requires a collective community effort to change that.

Our new Community Quest video shows how investors, innovators, regulators, patients, insurers—and you—make new treatments possible, accessible, and affordable.

Open letter regarding proposed FDA budget cuts — No Patient Left Behind

What does the FDA's expertise and regulatory transparency mean for you?

Shehnaaz Suliman, Gunnar Esiason, and @peterkolchinsky.bsky.social share how the FDA helps bring new medicines to US patients.

Thanks for their work supporting American innovation!

www.nopatientleftbehind.org/open-letter-...

It’s time for USTR to prioritize biopharmaceutical trade policy to ensure these treatments are affordable to patients who need them and allows innovation to continue.

Other wealthy nations continue to undervalue the impact of life-saving medicines, paying far less for them while still benefiting from our scientific breakthroughs. These other wealthy countries, our trade competitors, don't have true markets for medicines.

Protect American Innovation — No Patient Left Behind

At #JPM25, biopharma investors and innovators sounded the alarm: America drives global medical innovation, but we need other countries to step up to keep medicine affordable. Watch the video and read the transcript here:
www.nopatientleftbehind.org/protect-amer...

Open letter regarding proposed FDA budget cuts — No Patient Left Behind

The US is the undisputed global leader in biopharmaceutical innovation thanks in no small part to the @fda.gov scientific expertise and regulatory transparency.😍 Please add your name in support of our nation's innovation ecosystem and competitive advantage
www.nopatientleftbehind.org/open-letter-...

Health Insurers Deny 850 Million Claims a Year. The Few Who Appeal Often Win. Patients who contest denials face a daunting process, but many are successful. “This appeal saved my life.”

Nuts. ⁦@wsjwernau.bsky.social “Health plans process more than 5 billion claims annually. @kff.org says ~850M are denied. Less than 1% of patients appeal.” ⁦Still time for CMS
⁩to fix prior auth rules to better protect patients in time for ‘26 plan year. www.wsj.com/health/healt...

We are still accepting applications for this spring's NPLB Biotech Fellowship program!

What can fellows expect? What will you learn? Watch this video from NPLB's founder @peterkolchinsky.bsky.social to find out 👇🏻

Apply at nopatientleftbehind.org/fellowship. The deadline to apply is February 15.

Open letter regarding proposed FDA budget cuts — No Patient Left Behind

**NEW LETTER** Please add your name in support of properly funding FDA's scientific expertise and regulatory transparency. 🔬FDA experts work on important, breakthrough science. Americans should not have to wait longer for new treatments. Read and click: www.nopatientleftbehind.org/open-letter-...

.@miafarrow.bsky.social Thank you for highlighting!! Please consider adding your name in support of merit-based, government-supported basic research. U.S. biomedical research leadership thrives on stability, transparency and long-term commitment. nopatientleftbehind.org/defending-th...

Please add your name in support of the US biotech ecosystem. Stand up for merit-based, government-supported basic research that fuels US leadership in biomedical progress.
👏 Scientific research thrives on stability, transparency and long-term commitment.
www.nopatientleftbehind.org/defending-th...

Thank you @biocentury.bsky.social for publishing luke evnin, @peterkolchinsky.bsky.social, & @peterlrubin.bsky.social call to action in support of biomedical research critical to our nation's health and economic strength. Join our call to action here:
www.nopatientleftbehind.org/defending-th...

Health economists, patient advocates, and industry leaders at #ISPOREurope met to enjoy tapas and discuss the latest research at an NPLB networking reception.

It was great to connect with conference attendees and demonstrate an early version of our upcoming GCEA calculator.